Friday 6-13-2014 Cel-Sci Corp (CVM) $CVM opened at 1.13 hitting the high price of 1.15 and a day low of 1.07 with a total volume of 230,833. CVM had a previous close of 1.15 and has been seeing an average volume of 473,745.
Overall Average: 40% Sell
Recent stock forum discussions about CVM http://investorshangout.com/search?q=CVM&...mp;yt0=Go!
CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Tue Jun 03, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014. (full story)
CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom
Business Wire - Mon Jun 02, 8:30AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin the Company's Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the United Kingdom (UK). The UK becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer. (full story)
Hot Stock: CEL-SCI, Shares Gain 8.4% (CVM)
Comtex SmarTrend(R) - Thu May 29, 12:44PM CDT
CEL-SCI (AMEX:CVM) is one of today's best performing low-priced stocks, up 8.4% to $1.16 on 1.1x average daily volume. CEL-SCI has traded 936,000 shares thus far today, vs. average volume of 873,000 shares per day. The stock has outperformed the Dow (8.4% to the Dow's 0.0%) and outperformed the S&P 500 (8.4% to the S&P's 0.2%) during today's trading. (full story)
Global Myocarditis Therapeutics Pipeline Report 2014
M2 - Thu May 29, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvmqgt/myocarditis) has announced the addition of the "Myocarditis - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Novartis AG - CEL-SCI Corporation Scope - The report provides a snapshot of the global therapeutic landscape of Myocarditis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocarditis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocarditis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocarditis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/vv...yocarditis (full story)
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2014
M2 - Wed May 28, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmzf2f/severe_acute) has announced the addition of the "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Novavax, Inc. - CEL-SCI Corporation - Protein Potential, LLC - AlphaVax, Inc. - aRigen Pharmaceuticals, Inc. - GeneCure LLC - Protein Sciences Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/cm...vere_acute (full story)
West Nile Virus Infections Therapeutics Pipeline Review 2014 - Review of 4 Companies & 13 Drug Profiles
M2 - Tue May 27, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n66lgc/west_nile_virus) has announced the addition of the "West Nile Virus Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for West Nile Virus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for West Nile Virus Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for West Nile Virus Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the West Nile Virus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the West Nile Virus Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - CEL-SCI Corporation - Hemispherx Biopharma, Inc. - Kineta, Inc. - Hawaii Biotech, Inc. Drug Profiles - interferon alfa-n3 (human leukocyte derived) - HBV-002 - CEL-1000 - Innate Immune Agonists - VG-WNV - Plant Derived Hu-E16 Monoclonal Antibody - Innate Immune Adjuvants - Vaccine For West Nile Virus Infections - BG-323 - Small Molecules to Inhhibit Serine Protease for Viral Infections - Monoclonal Antibody for West Nile Virus Infection - Small Molecule Inhibitors of NS3 Protease for Dengue and West Nile Virus Infections - ETX-112 For more information visit http://www.researchandmarkets.com/research/n6...nile_virus (full story)
University of Cincinnati Cancer Institute's Comprehensive Head and Neck Cancer Center Joins CEL-SCI'S Phase III Trial
Business Wire - Tue May 27, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that the University of Cincinnati Cancer Institute is the latest medical center in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). CEL-SCI's study is already active in dozens of clinical centers in 12 countries and is expected to expand to a total of 20 countries with an estimated 880 patients to be enrolled by the end of 2015. According to the American Society of Clinical Oncology, head and neck cancers account for about 3% to 5% of all cancers in the United States. (full story)
Three biotechs stocks with positive institutional transactions, good price to cash ratios and "buy" recommendations from street analysts
ACCESSWIRE - Thu May 22, 7:09AM CDT
LOS ANGELES / ACCESSWIRE / May 22, 2014 / The names of big-board biotechnology listed firms IsoRay, Inc. (NYSE MKT: ISR), CEL-SCI Corporation (NYSE MKT: CVM), and Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), came up after we set out to find low price biotech stocks with market caps in the $50m to $300m range which, based on a fixed set of fundamental and technical criteria, might be hinting at bullish investment trade sentiments. (full story)
Biotech Stocks Technical Data -- Research on Alnylam Pharma, Regeneron Pharma, Cel-Sci, and Synta Pharma
PR Newswire - Tue May 13, 9:15AM CDT
On Monday, May 12, 2014, the NASDAQ Composite ended at 4,143.86, up 1.77%, the Dow Jones Industrial Average finished the day 0.68% higher at 16,695.47, and the S&P 500 closed at 1,896.65, up 0.97%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, and the index has advanced 4.74% in the last one month. Investor-Edge has initiated coverage on the following equities: Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Cel-Sci Corporation (NYSE MKT: CVM) and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free technical research on ALNY, REGN, CVM and SNTA can be downloaded upon signing up at: (full story)
CEL-SCI Corporation Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Tue May 13, 7:02AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2014. (full story)
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer (full story)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation (full story)
CEL-SCI Reports April 2014 is Another Record Month for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Thu May 01, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of April 2014 the Company enrolled 21 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This marks a substantial increase over the previous monthly record of 14 patients in March 2014. (full story)
Global Oral Cavity (Mouth) Cancer Global Clinical Trials Review Report 2014
M2 - Thu May 01, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmqsjv/oral_cavity) has announced the addition of the "Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" provides data on the Oral Cavity (Mouth) Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Cavity (Mouth) Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Cavity (Mouth) Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - C. H. Boehringer Sohn AG & Co. KG - Vical Incorporated - Pfizer Inc. - Galera Therapeutics LLC - CEL-SCI Corporation - National Cancer Institute - Roswell Park Cancer Institute - The University of Chicago - The University of Texas M. D. Anderson Cancer Center - NCIC Clinical Trials Group - University of Washington - Radiation Therapy Oncology Group - Tata Memorial Hospital - University of Miami Sylvester Comprehensive Cancer Center - Fox Chase Cancer Center For more information visit http://www.researchandmarkets.com/research/lm...ral_cavity (full story)
CEL-SCI Corporation Receives $3 Million from Warrant Exercises
Business Wire - Tue Apr 29, 7:31AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has received approximately $3 million through the exercise of warrants by investors to purchase the Company's common stock over the past 45 days. These $3 million are in addition to the $10 million raised in a public offering that closed on April 17, 2014. Proceeds from the warrant exercises and the public offering will be used to fund CEL-SCI's Phase III head and neck cancer clinical trial, other research and development, and general and administrative expenses. (full story)
Southern Illinois University School of Medicine Becomes Clinical Site for CEL-SCI's Global Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Mon Apr 28, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated another U.S. clinical site at Southern Illinois University School of Medicine's Simmons Cancer Institute in Springfield, Illinois. The Illinois site, which has become part of the world's largest Phase III trial for head and neck cancer with dozens of hospitals and clinical centers in 12 countries, has now officially joined the study. According to the National Cancer Institute, researchers estimated that about 52,000 men and women in the U.S. will be diagnosed with head and neck cancers annually. (full story)
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex (full story)
CEL-SCI to Sponsor Symposium on Multikine at European Congress on Head & Neck Oncology 2014
Business Wire - Tue Apr 22, 7:31AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that the Company is a Gold Sponsor of the European Congress on Head and Neck Oncology (ECHNO 2014), which will be held in Liverpool, England from April 24th through 26th, 2014. CEL-SCI will sponsor a symposium regarding its investigational immunotherapy candidate Multikine(R)* (Leukocyte Interleukin, Injection) and its ongoing Phase III head and neck cancer trial with Multikine. Company representatives will be available at conference booth #10. (full story)
CEL-SCI concludes USD10m in public offering
M2 - Fri Apr 18, 5:27AM CDT
Oncology company CEL-SCI (NYSE MKT:CVM) said on Thursday that it has raised USD10m from a public offering of units. (full story)
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $10 Million
Business Wire - Thu Apr 17, 10:55AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 7,128,229 shares of common stock and warrants to purchase an aggregate of 1,782,057 shares of common stock. The units were sold at a price of $1.40 per unit and resulted in aggregate gross proceeds of approximately $10 million, prior to deducting underwriting commissions and offering expenses. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire on October 17, 2014, and have an exercise price of $1.58 per share. (full story)
Overall Average: 40% Sell
Recent stock forum discussions about CVM http://investorshangout.com/search?q=CVM&...mp;yt0=Go!
CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Tue Jun 03, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014. (full story)
CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom
Business Wire - Mon Jun 02, 8:30AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin the Company's Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the United Kingdom (UK). The UK becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer. (full story)
Hot Stock: CEL-SCI, Shares Gain 8.4% (CVM)
Comtex SmarTrend(R) - Thu May 29, 12:44PM CDT
CEL-SCI (AMEX:CVM) is one of today's best performing low-priced stocks, up 8.4% to $1.16 on 1.1x average daily volume. CEL-SCI has traded 936,000 shares thus far today, vs. average volume of 873,000 shares per day. The stock has outperformed the Dow (8.4% to the Dow's 0.0%) and outperformed the S&P 500 (8.4% to the S&P's 0.2%) during today's trading. (full story)
Global Myocarditis Therapeutics Pipeline Report 2014
M2 - Thu May 29, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvmqgt/myocarditis) has announced the addition of the "Myocarditis - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Novartis AG - CEL-SCI Corporation Scope - The report provides a snapshot of the global therapeutic landscape of Myocarditis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocarditis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocarditis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocarditis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/vv...yocarditis (full story)
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2014
M2 - Wed May 28, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmzf2f/severe_acute) has announced the addition of the "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Novavax, Inc. - CEL-SCI Corporation - Protein Potential, LLC - AlphaVax, Inc. - aRigen Pharmaceuticals, Inc. - GeneCure LLC - Protein Sciences Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/cm...vere_acute (full story)
West Nile Virus Infections Therapeutics Pipeline Review 2014 - Review of 4 Companies & 13 Drug Profiles
M2 - Tue May 27, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n66lgc/west_nile_virus) has announced the addition of the "West Nile Virus Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for West Nile Virus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for West Nile Virus Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for West Nile Virus Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the West Nile Virus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the West Nile Virus Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - CEL-SCI Corporation - Hemispherx Biopharma, Inc. - Kineta, Inc. - Hawaii Biotech, Inc. Drug Profiles - interferon alfa-n3 (human leukocyte derived) - HBV-002 - CEL-1000 - Innate Immune Agonists - VG-WNV - Plant Derived Hu-E16 Monoclonal Antibody - Innate Immune Adjuvants - Vaccine For West Nile Virus Infections - BG-323 - Small Molecules to Inhhibit Serine Protease for Viral Infections - Monoclonal Antibody for West Nile Virus Infection - Small Molecule Inhibitors of NS3 Protease for Dengue and West Nile Virus Infections - ETX-112 For more information visit http://www.researchandmarkets.com/research/n6...nile_virus (full story)
University of Cincinnati Cancer Institute's Comprehensive Head and Neck Cancer Center Joins CEL-SCI'S Phase III Trial
Business Wire - Tue May 27, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that the University of Cincinnati Cancer Institute is the latest medical center in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). CEL-SCI's study is already active in dozens of clinical centers in 12 countries and is expected to expand to a total of 20 countries with an estimated 880 patients to be enrolled by the end of 2015. According to the American Society of Clinical Oncology, head and neck cancers account for about 3% to 5% of all cancers in the United States. (full story)
Three biotechs stocks with positive institutional transactions, good price to cash ratios and "buy" recommendations from street analysts
ACCESSWIRE - Thu May 22, 7:09AM CDT
LOS ANGELES / ACCESSWIRE / May 22, 2014 / The names of big-board biotechnology listed firms IsoRay, Inc. (NYSE MKT: ISR), CEL-SCI Corporation (NYSE MKT: CVM), and Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), came up after we set out to find low price biotech stocks with market caps in the $50m to $300m range which, based on a fixed set of fundamental and technical criteria, might be hinting at bullish investment trade sentiments. (full story)
Biotech Stocks Technical Data -- Research on Alnylam Pharma, Regeneron Pharma, Cel-Sci, and Synta Pharma
PR Newswire - Tue May 13, 9:15AM CDT
On Monday, May 12, 2014, the NASDAQ Composite ended at 4,143.86, up 1.77%, the Dow Jones Industrial Average finished the day 0.68% higher at 16,695.47, and the S&P 500 closed at 1,896.65, up 0.97%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, and the index has advanced 4.74% in the last one month. Investor-Edge has initiated coverage on the following equities: Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Cel-Sci Corporation (NYSE MKT: CVM) and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free technical research on ALNY, REGN, CVM and SNTA can be downloaded upon signing up at: (full story)
CEL-SCI Corporation Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Tue May 13, 7:02AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2014. (full story)
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer (full story)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation (full story)
CEL-SCI Reports April 2014 is Another Record Month for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Thu May 01, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of April 2014 the Company enrolled 21 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This marks a substantial increase over the previous monthly record of 14 patients in March 2014. (full story)
Global Oral Cavity (Mouth) Cancer Global Clinical Trials Review Report 2014
M2 - Thu May 01, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmqsjv/oral_cavity) has announced the addition of the "Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" provides data on the Oral Cavity (Mouth) Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Cavity (Mouth) Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Cavity (Mouth) Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - C. H. Boehringer Sohn AG & Co. KG - Vical Incorporated - Pfizer Inc. - Galera Therapeutics LLC - CEL-SCI Corporation - National Cancer Institute - Roswell Park Cancer Institute - The University of Chicago - The University of Texas M. D. Anderson Cancer Center - NCIC Clinical Trials Group - University of Washington - Radiation Therapy Oncology Group - Tata Memorial Hospital - University of Miami Sylvester Comprehensive Cancer Center - Fox Chase Cancer Center For more information visit http://www.researchandmarkets.com/research/lm...ral_cavity (full story)
CEL-SCI Corporation Receives $3 Million from Warrant Exercises
Business Wire - Tue Apr 29, 7:31AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has received approximately $3 million through the exercise of warrants by investors to purchase the Company's common stock over the past 45 days. These $3 million are in addition to the $10 million raised in a public offering that closed on April 17, 2014. Proceeds from the warrant exercises and the public offering will be used to fund CEL-SCI's Phase III head and neck cancer clinical trial, other research and development, and general and administrative expenses. (full story)
Southern Illinois University School of Medicine Becomes Clinical Site for CEL-SCI's Global Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Mon Apr 28, 7:30AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated another U.S. clinical site at Southern Illinois University School of Medicine's Simmons Cancer Institute in Springfield, Illinois. The Illinois site, which has become part of the world's largest Phase III trial for head and neck cancer with dozens of hospitals and clinical centers in 12 countries, has now officially joined the study. According to the National Cancer Institute, researchers estimated that about 52,000 men and women in the U.S. will be diagnosed with head and neck cancers annually. (full story)
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex (full story)
CEL-SCI to Sponsor Symposium on Multikine at European Congress on Head & Neck Oncology 2014
Business Wire - Tue Apr 22, 7:31AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that the Company is a Gold Sponsor of the European Congress on Head and Neck Oncology (ECHNO 2014), which will be held in Liverpool, England from April 24th through 26th, 2014. CEL-SCI will sponsor a symposium regarding its investigational immunotherapy candidate Multikine(R)* (Leukocyte Interleukin, Injection) and its ongoing Phase III head and neck cancer trial with Multikine. Company representatives will be available at conference booth #10. (full story)
CEL-SCI concludes USD10m in public offering
M2 - Fri Apr 18, 5:27AM CDT
Oncology company CEL-SCI (NYSE MKT:CVM) said on Thursday that it has raised USD10m from a public offering of units. (full story)
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $10 Million
Business Wire - Thu Apr 17, 10:55AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 7,128,229 shares of common stock and warrants to purchase an aggregate of 1,782,057 shares of common stock. The units were sold at a price of $1.40 per unit and resulted in aggregate gross proceeds of approximately $10 million, prior to deducting underwriting commissions and offering expenses. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire on October 17, 2014, and have an exercise price of $1.58 per share. (full story)
